How Long Can You Live With a Heart Tumor?

Survival with a heart tumor ranges from decades to months, and the single biggest factor is whether the tumor is benign or malignant. Roughly three out of four primary cardiac tumors are benign, and after surgical removal, five-year survival sits around 83% or higher. Malignant primary heart tumors tell a starkly different story, with a median survival of just seven months. The gap between those two numbers captures how misleading it can be to talk about “heart tumors” as a single category.

Benign Heart Tumors Have an Excellent Long-Term Outlook

The most common heart tumor by a wide margin is the myxoma, a non-cancerous growth that typically develops in the left atrium. Myxomas account for roughly half to 70 percent of all benign cardiac tumors, and they are almost always curable with surgery.¹ One study tracking 403 myxoma patients reported an overall survival rate of about 95 percent over a mean follow-up of four and a half years.² Extend the time horizon further and the numbers remain encouraging: a 40-year review of 63 patients found an 85 percent survival rate at 20 years after surgery.³ Another series followed patients for up to 24 years and reported 74 percent overall survival and a recurrence-free rate of 95 percent over that span.⁴

For a single, sporadic myxoma removed with clean margins, the practical message is that most people return to normal life and stay healthy for decades. Late deaths in these long-term series are often due to age-related conditions or concurrent heart disease rather than the tumor itself. The risk factors for dying after myxoma surgery are not especially mysterious: older age at diagnosis, having other serious medical conditions, and needing additional heart procedures all worsen the odds.²

When Benign Tumors Come Back

Myxoma recurrence after surgery is uncommon in most people, hovering around two to three percent. But there is an important exception: people with Carney complex, a rare inherited condition that predisposes individuals to multiple myxomas and other tumors throughout the body. In these patients, the recurrence rate jumps to roughly 22 percent.⁵

A study from a single institution tracking 24 Carney complex patients with myxomas found that more than half experienced at least one recurrence, with a median time to the first recurrence of about seven and a half years. Freedom from any recurrence dropped to roughly 17 percent at ten years. Yet here is the counterintuitive part: long-term survival in these patients was 100 percent at both 10 and 15 years.⁶ In other words, the tumors kept coming back, but the patients kept surviving them because each recurrence was treatable surgically. A larger review of Carney complex patients found that 44 percent had at least one recurrence, with a mean time to first recurrence of about four years. Some patients went through four separate recurrences.⁷

The upshot is that even among the highest-risk group for benign cardiac tumors, recurrence is a chronic management problem rather than a death sentence. Regular imaging surveillance for years after surgery is the standard approach, especially within the first decade when the recurrence risk is highest.

Primary Malignant Heart Tumors Are a Different Reality

When a heart tumor turns out to be cancerous and it originated in the heart itself, the prognosis changes dramatically. The most common primary malignant cardiac tumor is angiosarcoma, which accounts for roughly 30 to 43 percent of cardiac sarcomas depending on the series.¹ A large U.S. population-based analysis found that median survival for primary cardiac sarcoma was seven months. One-year survival was about 41 percent, and by five years only around one in ten patients was still alive.⁸

Part of the reason for these grim numbers is that cardiac sarcomas are often diagnosed late. Symptoms like shortness of breath, chest pain, fatigue, and fluid buildup mimic far more common heart conditions such as heart failure, pericarditis, or valve disease. Clinicians who encounter a mass in the heart often think first of the much more likely myxoma or a blood clot. That initial working diagnosis can lead to a surgical approach not designed for cancer, potentially compromising the quality of the resection.⁹ By the time the malignancy is confirmed, the tumor may already have invaded surrounding tissue or metastasized.

How Surgical Margins Shape Survival in Cardiac Sarcomas

Surgery remains the single most important treatment for primary cardiac sarcomas, and it offers the clearest survival benefit among available options.¹⁰ But the extent of the resection matters enormously. The key distinction is between a complete removal with clean margins and an incomplete resection where cancer cells remain at the cut edge. One study of right-sided heart sarcomas found that patients whose tumors were completely removed had a median survival of 27 months and a five-year survival rate of 36 percent. When cancer was left behind at the margin, median survival collapsed to four months and nobody reached the five-year mark.¹¹

Another single-institution experience found an even more striking difference: patients with microscopically clean margins survived a median of 58 months compared to 11 months for those with positive margins.¹² That gap, roughly five years versus one year, underscores why planning the surgery with cancer principles in mind from the start matters so much. Complete resection remains the gold standard for these rare tumors.¹³

Following surgery, chemotherapy and radiation can roughly double median survival. One analysis showed that patients receiving post-operative treatment survived a median of 19 months compared to eight months for surgery alone.¹⁴ There is also early evidence that newer treatments like antiangiogenic agents and immunotherapy may improve outcomes, though data remain limited.¹⁵

Heart Transplantation for Cardiac Sarcomas

When a cardiac sarcoma cannot be fully removed because it is too deeply embedded in the heart muscle, transplantation is sometimes considered. The reality, though, is that the data on transplant outcomes for cardiac sarcomas are mixed and limited. Angiosarcoma, the most common and aggressive type, does particularly poorly after transplant because it tends to recur quickly even after the diseased heart is replaced. Lower-grade, less aggressive tumor types appear to benefit more, but there is still no clear consensus on which patients are good candidates.¹⁶ Transplant for cardiac sarcoma remains a case-by-case decision rather than a standard recommendation.

Cancer That Has Spread to the Heart

Heart tumors that started elsewhere in the body and metastasized to the heart are actually far more common than tumors that originate in the heart. Autopsy studies suggest that about ten percent of patients with widely spread cancer develop cardiac metastases, though only a small fraction are ever diagnosed during life because they rarely cause symptoms of their own.¹

When cardiac metastases are detected and treated, survival depends heavily on whether the underlying cancer responds to therapy. One study found that the overall 12-month survival rate after discovery of cardiac metastasis was 38 percent. Patients who continued treatment averaged about 27 months of survival, while those who stopped treatment survived a median of roughly seven months. When the cardiac metastasis itself responded to treatment, median survival stretched to nearly 56 months compared to about 13 months without a cardiac response.¹⁷ Treatment for cardiac metastases typically follows the treatment plan for the primary cancer, whether that is chemotherapy, targeted therapy, immunotherapy, or radiation. In rare cases, radiation and immune therapy have been used to palliate isolated cardiac metastases, though long-term survival remains uncommon.¹⁸

Heart Tumors in Children

The most common heart tumor in infants and children is the rhabdomyoma, which behaves very differently from the tumors described above. Rhabdomyomas are strongly associated with tuberous sclerosis complex and, in most cases, they shrink and disappear on their own without any treatment. One study found complete resolution in 20 out of 24 children followed over time, with at least some regression in every single patient.¹⁹ Surgery is reserved for children who develop dangerous heart rhythm problems or serious obstruction of blood flow.²⁰

A broader study of pediatric cardiac tumors requiring surgery found that more than 93 percent of survivors were alive, symptom-free, and without tumor recurrence or progression at a mean follow-up of nearly 12 years, even in cases where the initial resection was incomplete.²¹ For children whose tumors are not causing symptoms or affecting heart function, watchful waiting is often the appropriate approach, and most do well long-term.²²

How Heart Tumors Can Cause Sudden Death

Even benign heart tumors carry a risk that does not show up in survival-curve percentages: sudden cardiac death. A review of the literature identified 120 cases of sudden death attributed to primary cardiac tumors, and in 103 of those cases the tumors were histologically benign. Death occurred because of the tumor’s location, not its biology: a mass sitting in the wrong part of the heart can block a valve, obstruct blood flow, or disrupt the heart’s electrical conduction system.²³ Myxomas can cause valve obstruction or shed fragments that travel to the brain, causing strokes. Sarcomas can invade the heart muscle and conduction pathways, triggering fatal arrhythmias. In children, rhabdomyomas are known to trigger dangerous ventricular rhythm disturbances.²⁴

Embolism is the complication that brings many myxoma patients to attention in the first place. Tumors in the left atrium are especially prone to shedding emboli because fragments enter the arterial circulation and can block blood supply to the brain, limbs, or organs. One study found that left atrial location and aortic valve location were the strongest predictors of embolic events.²⁵ Reassuringly, once the tumor is removed, recurrent embolic events appear to be rare. Left atrial tumors also tend to carry lower overall mortality than tumors in other heart chambers, likely because their symptoms (strokes, shortness of breath with position changes) are dramatic enough to prompt diagnosis sooner.²⁶

Getting to a Diagnosis Faster

One of the most consequential variables in heart tumor survival is simply how quickly the tumor is found and correctly identified. Cardiac MRI has emerged as the best non-invasive tool for this, correctly classifying masses as benign or malignant about 95 percent of the time when compared with tissue diagnosis.²⁷ This is a meaningful advantage because it helps surgeons plan the right operation before they go in. When a mass is incorrectly assumed to be a benign myxoma, the surgical approach may not be aggressive enough to achieve the clean margins that make the difference between years and months for a sarcoma patient.

CT and MRI together also help distinguish tumors from blood clots, which is a common diagnostic pitfall. Clots in the heart can look remarkably similar to tumors on echocardiography, and treating someone for a tumor they do not have, or missing a tumor because it was assumed to be a clot, are both dangerous mistakes.²⁸ For any unexpected mass seen on a routine echocardiogram, the general recommendation is to follow up with advanced imaging before making treatment decisions.

Palliative Care and Its Underuse

For patients with malignant cardiac tumors that cannot be cured, palliative care is underutilized. A review of more than 1,400 patients hospitalized with primary malignant cardiac tumors in the United States found that only about 11 percent received a palliative care consultation. Those who did had significantly lower 30-day readmission rates compared to those who did not, suggesting that palliative involvement helped manage symptoms and transitions more effectively.²⁹ Given the short median survival for many malignant heart tumors, earlier integration of palliative care alongside active treatment could improve quality of life during whatever time remains. The reluctance to involve palliative care may partly reflect how uncommon these tumors are: many care teams simply have little experience managing them, and the instinct is often to pursue aggressive treatment without pausing to address symptom burden and goals of care simultaneously.

Putting the Numbers in Perspective

The survival landscape for heart tumors spans an enormous range. At one end, a child with a rhabdomyoma may never need treatment and will likely watch the tumor vanish on its own. An adult with a sporadic myxoma can expect decades of life after a routine surgical removal. At the other extreme, a patient diagnosed with cardiac angiosarcoma faces a median survival measured in months, though complete surgical resection with adjuvant therapy can push that into the range of one to five years for a subset of patients. Cardiac metastases fall somewhere in between, with outcomes tied tightly to how well the original cancer responds to treatment.

One broader lesson from the evidence is that these tumors are rare enough that most cardiologists and surgeons will encounter only a handful in their careers. Referral to a center with dedicated experience in cardiac tumors is worth pursuing whenever possible, because the surgical approach and the speed of accurate diagnosis matter far more here than they do for common cardiac procedures. A five-year survival rate drawn from a large database gives you the average, but for any individual patient, the specifics of tumor type, location, stage at diagnosis, completeness of resection, and response to follow-up treatment all interact to shape an outcome that may look nothing like the statistical mean.